Blog

This Under-the-Radar Drug Developer May Have an Answer for Patients With Severe COVID-19

Vanda Pharmaceuticals (NASDAQ: VNDA) may not be a household name, but it could boost your net worth. The specialty pharma's two marketed drugs generated sales totaling $227.2 million in 2019 and $58

TheMotleyFool

0

Here's Why No One's Smiling About SmileDirectClub's Q1 Results

If you're the kind of person who looks at a glass of water as half empty, 2020 has been disastrous for SmileDirectClub (NASDAQ: SDC). Its stock has been cut in half from its highs in February. On

TheMotleyFool

0

iPhone Sales in China Are Reportedly Growing Sharply

Apple's (NASDAQ: AAPL) Greater China segment weighed on the tech giant's results in fiscal Q2, which ended on March 28, 2020. After a strong January, demand for Apple's products in the market fell

TheMotleyFool

0

Is Costco a Great Dividend Stock?

The dividend isn't the first thing most investors think about when they're looking at Costco (NASDAQ: COST) stock. Compared to peers like Walmart (NYSE: WMT), the warehouse retailer returns a small

TheMotleyFool

0

Merck Just Made a Gamble That Smart Investors Should Bet on Too

While its blockbuster cancer therapeutic Keytruda continues to excite pharma investors, a piece of equally important news is that Merck (NYSE: MRK) is in the midst of a major strategic effort to

TheMotleyFool

0

Here's Who's Suing the U.S. Treasury Over Stimulus Checks

Under the Coronavirus Aid, Relief, and Economic Security (CARES) Act, stimulus payments of $1,200 per adult and $500 per dependent child are being made available to most individuals and families.

TheMotleyFool

0

Is Now a Good Time To Buy Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ: NBIX) had a big day Tuesday, the latest in a string of good days. Since the stock bottomed out at $75.11 almost two months ago, it climbed as high as $119.65 on

TheMotleyFool

0

2 Recession-Proof Healthcare Stocks to Buy in 2020

In the first quarter of 2020, the U.S. GDP declined by 4.8% year over year. For the first time since 2008, the global economy is heading toward a recession (defined by two consecutive quarters of

TheMotleyFool

0

Where Will Moderna Be in 5 Years?

Clinical-stage biotech Moderna (NASDAQ: MRNA) has been in the coronavirus spotlight in recent weeks because it's further along in the quest for a COVID-19 vaccine than any other company. There's no

TheMotleyFool

0

Can Social Security Survive the COVID-19 Crisis?

Millions of seniors depend on the income they receive from Social Security to pay the bills in retirement. In fact, without those benefits, a large number of seniors would virtually be living in

TheMotleyFool

0

3 Warren Buffett Stocks I'll Never Sell

Although Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett's annual performance has been a bit hit and miss as of late, it's undeniable that his buy-and-hold investment strategy has

TheMotleyFool

0

Why Has VectoIQ Acquisition Stock Jumped 130% Since May 1?

Shares of VectoIQ Acquisition (NASDAQ: VTIQ) have had a huge run since the beginning of May, rising over 130% through the market's close on May 13.

It's not hard to figure out why: VectoIQ, a

TheMotleyFool

0

3 Top Bank Stocks to Buy Right Now

Bank stocks have taken a hit since the coronavirus pandemic struck the economy, but most experts say the banks are not the main concern in this crisis, like they were during the Great Recession. The

TheMotleyFool

0

Opinion: Stock Market Crash Round 2 Is Coming

For nearly the past three months, Wall Street and investors have dealt with some of the wildest volatility they've ever seen. In a span of 33 calendar days, the benchmark S&P 500 (SNPINDEX: ^GSPC)

TheMotleyFool

0